aTyr Pharma Inc
ATYR4.940USD
+0.240+5.11%
Market hours （ET）Quotes delayed by 15 min
439.67MMarket Cap
LossP/E TTM
More Details of aTyr Pharma Inc Company
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).
Company Info
Ticker SymbolATYR
Company nameaTyr Pharma Inc
IPO dateMay 07, 2015
CEODr. Sanjay S. Shukla, M.D.
Number of employees56
Security typeOrdinary Share
Fiscal year-endMay 07
Address10240 Sorrento Valley Road
CitySAN DIEGO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92121
Phone18587318389
Websitehttps://www.atyrpharma.com/
Ticker SymbolATYR
IPO dateMay 07, 2015
CEODr. Sanjay S. Shukla, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Sanjay S. Shukla, M.D.
Dr. Sanjay S. Shukla, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
146.92K
--
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
56.00K
+833.33%
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
9.75K
+62.50%
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
6.00K
--
Dr. Paul R. Schimmel, Ph.D.
Dr. Paul R. Schimmel, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sara L. Zaknoen, M.D.
Dr. Sara L. Zaknoen, M.D.
Independent Director
Independent Director
--
--
Ms. Jill M. Broadfoot
Ms. Jill M. Broadfoot
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Eric S. Benevich
Mr. Eric S. Benevich
Independent Director
Independent Director
--
--
Ms. Nancy E. Denyes, J.D.
Ms. Nancy E. Denyes, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Sanjay S. Shukla, M.D.
Dr. Sanjay S. Shukla, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
146.92K
--
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
56.00K
+833.33%
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
9.75K
+62.50%
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
6.00K
--
Dr. Paul R. Schimmel, Ph.D.
Dr. Paul R. Schimmel, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sara L. Zaknoen, M.D.
Dr. Sara L. Zaknoen, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Federated Hermes Global Investment Management Corp.
16.48%
Fidelity Management & Research Company LLC
14.49%
The Vanguard Group, Inc.
5.23%
Octagon Capital Advisors LP
3.99%
Point72 Asset Management, L.P.
3.20%
Other
56.62%
Shareholders
Shareholders
Proportion
Federated Hermes Global Investment Management Corp.
16.48%
Fidelity Management & Research Company LLC
14.49%
The Vanguard Group, Inc.
5.23%
Octagon Capital Advisors LP
3.99%
Point72 Asset Management, L.P.
3.20%
Other
56.62%
Shareholder Types
Shareholders
Proportion
Investment Advisor
27.84%
Investment Advisor/Hedge Fund
20.75%
Hedge Fund
20.46%
Individual Investor
2.23%
Research Firm
1.92%
Pension Fund
0.20%
Bank and Trust
0.05%
Venture Capital
0.02%
Other
26.52%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
160
65.39M
73.47%
+2.57M
2025Q1
162
64.83M
72.99%
-691.51K
2024Q4
140
57.60M
68.66%
-6.81M
2024Q3
117
50.41M
67.53%
-11.03M
2024Q2
113
50.68M
74.24%
-3.06M
2024Q1
111
44.35M
66.05%
-8.23M
2023Q4
110
43.49M
75.20%
-5.05M
2023Q3
109
43.22M
76.15%
+288.84K
2023Q2
108
41.84M
78.83%
+2.15M
2023Q1
98
40.77M
78.21%
+15.80M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Federated Hermes Global Investment Management Corp.
14.67M
16.48%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
12.89M
14.49%
+796.10K
+6.58%
Mar 31, 2025
The Vanguard Group, Inc.
4.01M
4.5%
+401.81K
+11.15%
Mar 31, 2025
Octagon Capital Advisors LP
3.55M
3.99%
+2.65M
+294.67%
Mar 31, 2025
Point72 Asset Management, L.P.
2.84M
3.2%
-2.04M
-41.76%
Mar 31, 2025
Tikvah Management LLC
2.46M
2.76%
--
--
Mar 31, 2025
Susquehanna International Group, LLP
1.73M
1.95%
+945.24K
+119.98%
Mar 31, 2025
Woodline Partners LP
1.68M
1.89%
-1.41K
-0.08%
Mar 31, 2025
UBS Financial Services, Inc.
1.61M
1.81%
+1.38M
+600.20%
Mar 31, 2025
Millennium Management LLC
1.60M
1.8%
+1.23M
+334.53%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco Dorsey Wright SmallCap Momentum ETF
0.42%
iShares Micro-Cap ETF
0.1%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
ProShares Hedge Replication ETF
0.02%
ProShares UltraPro Russell2000
0.02%
iShares Russell 2000 Growth ETF
0.02%
Global X Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
iShares Russell 2000 ETF
0.01%
iShares Russell 2000 Value ETF
0%
View more
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.42%
iShares Micro-Cap ETF
Proportion0.1%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.03%
ProShares Hedge Replication ETF
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.02%
iShares Russell 2000 Growth ETF
Proportion0.02%
Global X Russell 2000 ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.02%
iShares Russell 2000 ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
